NEW YORK, Jan. 28, 2019 /PRNewswire/ -- This report analyzes the worldwide markets for Ion Channel Modulators in US$ Million.
Read the full report: https://www.reportlinker.com/p01171462
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
The report profiles 39 companies including many key and niche players such as:
- Allergan plc
- AstraZeneca
- Bayer HealthCare Pharmaceuticals
- Biogen, Inc.
- GlaxoSmithKline Plc
- H. Lundbeck A/S
Read the full report: https://www.reportlinker.com/p01171462
ION CHANNEL MODULATORS MCP-6
MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1. OUTLOOK
Ion Channel Modulators - A Receding Market
Current and Future Analysis
Aging Population: Creating Need for More Efficient and Safe Drugs
Table 1: Global Population Worldwide: Percentage Share Breakdown by Age Group for the year 2025 (includes corresponding Graph/Chart)
Table 2: Global Population of People Aged 65+ Years (In Million) for the Years 2012, 2020 & 2050 (includes corresponding Graph/Chart)
Competitive Scenario
Table 3: Leading Ion Channel Modulators Worldwide: 2
(Percentage Breakdown of Revenues) (includes corresponding Graph/Chart)
Patent Expiries of Select Ion Channel Modulators
2. INDUSTRY OVERVIEW
Ion Channels - A Peek into Their Types, Functional Use and Diversity
Ion Channels - Difficult Drug Targets
Currently Available Ion Channel Modulating Drugs in the Market
Select Ion Channel Modulator Drugs by Mode of Action
Ion Channel Modulators by Therapeutic Indication
Cardiovascular Diseases/ Hypertension
Table 4: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
Table 5: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)
Table 6: Fatalities in Low Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart)
Table 7: Fatalities in Mid Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart)
Table 8: Fatalities in High Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD, Cancer, Injury, and Others (includes corresponding Graph/Chart)
Arrhythmia Treatment
Convulsions
Pain Management
Oncology
Diabetes
Ion Channel Modulation of Antiemetics
Ion Channel Modulators Find Extensive Use in Neglected Tropical Diseases
Other Therapeutic Areas
Ion Channel Screening Aided by APC
Growing Interest in Outsourcing of Ion Channel Services
Selectivity against Subtypes - Need of the Hour for Na Channel Blockers
Select First Gen Sodium Ion Channel Modulators and Indications
Sodium Channel Subtypes, Specific Tissues and Indications
Strong Potential Na Channel Blockers for Use in Neuropathic Pain
New Trial Questions Nifedipine€™s Use for Treating Chronic Chilblains
3. PRODUCT OVERVIEW
Ion Channel Modulators: An Introduction
Biological Significance of Ion Channels
Ion Channel Modulators as an Option for Treating Diseases
Types of Ion Channels
Voltage-Gated Ion Channels
Extracellular Ligand-gated Ion Channels
Intracellular Ligand-gated Ion Channels
4. RECENT INDUSTRY ACTIVITY
Xenon Pharmaceuticals Begins Phase I Trials on XEN1
Potassium Channel Opener
AstraZeneca Inks Agreement with Aspen for Residual Rights to its Anesthetics Portfolio
Parion Grants Global Rights for P-321 to Shire
Xenon Adds XEN1101 Potassium Channel Modulator to Its Pipeline
Alvogen Recalls 24 Lots of Nifedipine
Parion Commences Phase II Clinical Trial of P-321
AstraZeneca Sells Rights of Anesthetics to Aspen
AstraZeneca Inks Licensing Deal with CMS
Evotec and Asahi Collaborate for Screening of Ion Channel Targets
Catalyst Merges with Targacept
XRpro Acquires Pfizer€™s Ion Channel Biology Platform
Vertex and Parion Team Up to Develop ENaC Inhibitors
Parion Initiates Enrollment for Phase II Clinical Trial for P -1037 in Cystic Fibrosis
Biogen Idec Changes Name to Biogen
Biogen Idec Acquires Convergence Pharmaceuticals
Pfizer Wins Court Ruling to Block Generic Versions of Lyrica Upto 2018
Forest Labs Discontinues Namenda 5/10 mg Tablets, Launches Namenda XR
Forest Files Lawsuit against Namenda Generic Manufacturers
Cytocentrics Bioscience Selects Drug Safety Testing Center as its Distributor in Japanese Market
Zalicus Licenses Its Entire Sodium Channel Modulator Program to AnaBios Corporation
EPIRUS Merges with Zalicus
5. FOCUS ON SELECT GLOBAL PLAYERS
Allergan plc (Ireland)
AstraZeneca (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Biogen, Inc. (USA)
GlaxoSmithKline Plc. (UK)
H. Lundbeck A/S (Denmark)
Johnson & Johnson (USA)
Novartis AG (Switzerland)
Parion Sciences, Inc. (USA)
Pfizer, Inc. (USA)
Sanofi S.A. (France)
6. GLOBAL MARKET PERSPECTIVE
Table 9: World Recent Past, Current and Future Analysis for Ion Channel Modulators by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 10: World 8-Year Perspective for Ion Channel Modulators by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2015, 2017 & 2
(includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
A.Market Analysis
Current & Future Analysis
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 11: The US Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
2. CANADA
Market Analysis
Table 12: Canadian Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
3. JAPAN
A.Market Analysis
Current & Future Analysis
Strategic Corporate Developments
B.Market Analytics
Table 13: Japanese Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
4. EUROPE
Market Analysis
Table 14: European Recent Past, Current and Future Analysis for Ion Channel Modulators by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 15: European 8-Year Perspective for Ion Channel Modulators by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2017 & 2
(includes corresponding Graph/Chart)
4a. FRANCE
A.Market Analysis
Current & Future Analysis
Sanofi S.A. - A Key Player
B.Market Analytics
Table 16: French Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
4b. GERMANY
A.Market Analysis
Current & Future Analysis
Bayer HealthCare Pharmaceuticals - A Key German Player in the Ion Channel Modulator Market
B.Market Analytics
Table 17: German Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
4c. ITALY
Market Analysis
Table 18: Italian Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A.Market Analysis
Current & Future Analysis
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 19: The UK Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
4e. SPAIN
Market Analysis
Table 20: Spanish Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
4f. RUSSIA
Market Analysis
Table 21: Russian Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
4g. REST OF EUROPE
A.Market Analysis
Current & Future Analysis
Key Players
B.Market Analytics
Table 22: Rest of Europe Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
5. ASIA-PACIFIC
A.Market Analysis
Current & Future Analysis
Strategic Corporate Development
B.Market Analytics
Table 23: Asia-Pacific Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
6. REST OF WORLD
A.Market Analysis
Current & Future Analysis
Strategic Corporate Developments
B.Market Analytics
Table 24: Rest of World Recent Past, Current and Future Analysis for Ion Channel Modulators Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 39 (including Divisions/Subsidiaries - 41) The United States (18) Canada (2) Japan (1) Europe (19) - France (2) - Germany (2) - The United Kingdom (6) - Italy (2) - Rest of Europe (7) Asia-Pacific (Excluding Japan) (1)
Read the full report: https://www.reportlinker.com/p01171462
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article